Dimopoulos MA - Search Results

1

An overview of the role of carfilzomib in the treatment of multiple myeloma.

Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA. Ziogas DC, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897. doi: 10.1080/14656566.2017.1404575. Epub 2017 Nov 20. Expert Opin Pharmacother. 2017. PMID: 29134824 Review.

2

Current treatment options for myeloma.

Terpos E, Rahemtulla A, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2005 Jun;6(7):1127-42. doi: 10.1517/14656566.6.7.1127. Expert Opin Pharmacother. 2005. PMID: 15957967 Review.

3

Clinical implications of chromosomal abnormalities in multiple myeloma.

Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Leuk Lymphoma. 2006 May;47(5):803-14. doi: 10.1080/10428190500464104. Leuk Lymphoma. 2006. PMID: 16753864 Review.

4

Novel anti-myeloma agents and angiogenesis.

Anargyrou K, Dimopoulos MA, Sezer O, Terpos E. Anargyrou K, et al. Among authors: dimopoulos ma. Leuk Lymphoma. 2008 Apr;49(4):677-89. doi: 10.1080/10428190701861686. Leuk Lymphoma. 2008. PMID: 18398734 Review.

5

Bortezomib in multiple myeloma.

Terpos E, Roussou M, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Drug Metab Toxicol. 2008 May;4(5):639-54. doi: 10.1517/17425255.4.5.639. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484921 Review.

6

Applications of monoclonal antibodies for the treatment of hematological malignancies.

Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E. Migkou M, et al. Among authors: dimopoulos ma. Expert Opin Biol Ther. 2009 Feb;9(2):207-20. doi: 10.1517/14712590802650581. Expert Opin Biol Ther. 2009. PMID: 19236251 Review.

7

RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.

Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Biol Ther. 2009 Apr;9(4):465-79. doi: 10.1517/14712590902845610. Expert Opin Biol Ther. 2009. PMID: 19344283 Review.

8

Lenalidomide: an update on evidence from clinical trials.

Dimopoulos MA, Terpos E. Dimopoulos MA, et al. Blood Rev. 2010 Nov;24 Suppl 1:S21-6. doi: 10.1016/S0268-960X(10)70005-9. Blood Rev. 2010. PMID: 21126633

9

Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

Dimopoulos MA, Kastritis E. Dimopoulos MA, et al. Leuk Lymphoma. 2006 Nov;47(11):2271-2. doi: 10.1080/10428190600908620. Leuk Lymphoma. 2006. PMID: 17107895 No abstract available.

10

The evolving role of lenalidomide in the treatment of hematologic malignancies.

Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2007 Mar;8(4):497-509. doi: 10.1517/14656566.8.4.497. Expert Opin Pharmacother. 2007. PMID: 17309344 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,275 results

Search Page